Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company’s lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. On November 16, 2024, Seelos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Metrics to compare | SEELQ | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSEELQPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −0.3x | −0.5x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.0x | 0.8x | 2.6x | |
Price / LTM Sales | 0.0x | 1.7x | 3.3x | |
Upside (Analyst Target) | - | 173.2% | 45.4% | |
Fair Value Upside | Unlock | 19.7% | 7.7% | Unlock |